Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting anthracycline scaffold for designing DNA-targeting agents.

Methods in enzymology - 1 Jan 2001

Priebe W, Fokt I, Przewloka T, Chaires J B, Portugal J, Trent J O

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antibiotics, Antineoplastic
Share to Combinatorial Chemistry Techniques
Share to Daunorubicin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Design

Share to Magnetic Resonance Spectroscopy

Share to Thermodynamics

Share to X-Ray Diffraction

Source

Identifiers

PMID: 11494869
DOI: 10.1016/s0076-6879(01)40441-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting anthracycline scaffold for designing DNA-targeting agents.PMID 11494869Read ↗

Chromatin as an old and new anticancer targetSemantic proximity Read ↗

Molecular avenues in targeted doxorubicin cancer therapySemantic proximity Read ↗

New insights into the activities and toxicities of the old anticancer drug doxorubicinSemantic proximity Read ↗

Recent developments in topoisomerase-targeted cancer chemotherapySemantic proximity Read ↗

DNA Nanoflower Enables Controlled Co-Delivery of Antisense Oligodeoxynucleotide and Doxorubicin for Anti-breast Cancer TreatmentSemantic proximity Read ↗

Synthesis and characterization of Cu(II)-based anticancer chemotherapeutic agent targeting topoisomerase Iα: In vitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell linesSemantic proximity Read ↗

Designing drugs against heterogeneous targets.Semantic proximity Read ↗

Targeting DNA topoisomerase II in cancer chemotherapySemantic proximity Read ↗

Evolution of Nitrogen-Based Alkylating Anticancer AgentsSemantic proximity Read ↗

G-Quadruplex targeting ligands: A hope and a new horizon in Cancer TherapeuticsSemantic proximity Read ↗

Antitumor activity of sequence‐specific alkylating agents: Pyrolle‐imidazole CBI conjugates with indole linkerSemantic proximity Read ↗

Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.